×

AstraZeneca lung cancer drug combination misses goal in key study

LONDON, July 27 (Reuters) - AstraZeneca's combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday. (Reporting by Ben Hirschler)